Journal article
Canada’s Amendment to Patented Drug Price Regulation
Abstract
This Viewpoint reviews proposed changes to regulations governing Canada’s Patented Medicine Process Review Board, a group mandated by Canada’s government to ensure manufacturers do not charge excessive drug prices, including use of cost-utility analyses to define excessive pricing, revision of reference country comparisons, and reducing regulatory burdens for generic drugs.
Authors
Humphries B; Xie F
Journal
JAMA: The Journal of the American Medical Association, Vol. 321, No. 16, pp. 1565–1566
Publisher
American Medical Association (AMA)
Publication Date
April 23, 2019
DOI
10.1001/jama.2019.2280
ISSN
0098-7484